News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
40,125 Results
Type
Article (2573)
Company Profile (45)
Press Release (37506)
Multimedia
Podcasts (9)
Webinars (2)
Section
Business (14208)
Career Advice (78)
Deals (2110)
Drug Delivery (9)
Drug Development (4150)
Employer Resources (10)
FDA (444)
Job Trends (783)
News (20301)
Policy (1059)
Tag
Academia (144)
Allergies (7)
Alliances (3501)
ALS (6)
Alzheimer's disease (59)
Antibody-drug conjugate (ADC) (27)
Approvals (447)
Artificial intelligence (31)
Autoimmune disease (8)
Automation (2)
Bankruptcy (12)
Best Places to Work (476)
BIOSECURE Act (2)
Biosimilars (16)
Biotechnology (29)
Bladder cancer (8)
Brain cancer (7)
Breast cancer (44)
Cancer (324)
Cardiovascular disease (10)
Career advice (66)
Career pathing (1)
CAR-T (31)
CDC (1)
Cell therapy (81)
Cervical cancer (2)
Clinical research (3444)
Collaboration (199)
Company closure (2)
Compensation (104)
COVID-19 (185)
CRISPR (11)
C-suite (112)
Cystic fibrosis (7)
Data (418)
Denatured (6)
Depression (11)
Diabetes (17)
Diagnostics (488)
Digital health (2)
Diversity (2)
Diversity, equity & inclusion (1)
Drug discovery (36)
Drug pricing (10)
Duchenne muscular dystrophy (40)
Earnings (4501)
Editorial (5)
Employer branding (1)
Employer resources (8)
Events (6400)
Executive appointments (134)
FDA (589)
Friedreich's ataxia (4)
Frontotemporal dementia (1)
Funding (167)
Gene editing (32)
Generative AI (1)
Gene therapy (55)
GLP-1 (63)
Government (158)
Guidances (24)
Healthcare (710)
HIV (1)
Huntington's disease (5)
IgA nephropathy (12)
Immunology and inflammation (34)
Immuno-oncology (14)
Indications (4)
Infectious disease (197)
Inflammatory bowel disease (15)
Inflation Reduction Act (6)
Influenza (7)
Intellectual property (25)
Interviews (7)
IPO (1002)
IRA (7)
Job creations (294)
Job search strategy (62)
JPM (4)
Kidney cancer (6)
Labor market (11)
Layoffs (51)
Leadership (3)
Legal (215)
Liver cancer (6)
Longevity (1)
Lung cancer (28)
Lymphoma (12)
Machine learning (3)
Management (4)
Manufacturing (52)
MASH (14)
Medical device (314)
Medtech (315)
Mergers & acquisitions (1223)
Metabolic disorders (72)
Multiple sclerosis (22)
Neurodegenerative disease (27)
Neuropsychiatric disorders (10)
Neuroscience (164)
NextGen: Class of 2026 (353)
Non-profit (155)
Now hiring (11)
Obesity (32)
Opinion (17)
Ovarian cancer (17)
Pain (24)
Pancreatic cancer (21)
Parkinson's disease (11)
Partnered (4)
Patents (53)
Patient recruitment (25)
Peanut (1)
People (5879)
Pharmaceutical (5)
Phase 1 (1474)
Phase 2 (1705)
Phase 3 (919)
Pipeline (390)
Policy (16)
Postmarket research (30)
Preclinical (640)
Press Release (2)
Prostate cancer (7)
Psychedelics (3)
Radiopharmaceuticals (14)
Rare diseases (62)
Real estate (427)
Recruiting (5)
Regulatory (918)
Reports (7)
Research institute (149)
Resumes & cover letters (9)
Rett syndrome (1)
RNA editing (5)
RSV (1)
Schizophrenia (16)
Series A (46)
Series B (20)
Service/supplier (2)
Sickle cell disease (3)
Special edition (3)
Spinal muscular atrophy (2)
Sponsored (1)
Startups (498)
Stomach cancer (2)
Supply chain (4)
Tariffs (2)
The Weekly (3)
Vaccines (52)
Venture capital (15)
Weight loss (21)
Women's health (10)
Worklife (1)
Date
Last 7 days (39)
Last 30 days (153)
Last 365 days (2411)
2026 (211)
2025 (2438)
2024 (2610)
2023 (2858)
2022 (3750)
2021 (4048)
2020 (3471)
2019 (2063)
2018 (1556)
2017 (1795)
2016 (1624)
2015 (1836)
2014 (1369)
2013 (1190)
2012 (1397)
2011 (1332)
2010 (1185)
Location
Africa (44)
Alabama (3)
Arizona (18)
Asia (1947)
Australia (307)
California (1601)
Canada (241)
China (80)
Colorado (54)
Connecticut (16)
Delaware (5)
Europe (4016)
Florida (64)
Georgia (11)
Hawaii (2)
Idaho (3)
Illinois (21)
India (2)
Indiana (60)
Japan (17)
Kansas (14)
Kentucky (1)
Maryland (48)
Massachusetts (568)
Michigan (14)
Minnesota (22)
Mississippi (1)
Missouri (4)
Nebraska (1)
Nevada (3)
New Hampshire (4)
New Jersey (133)
New York (80)
North Carolina (131)
Northern California (781)
Ohio (44)
Oklahoma (2)
Oregon (6)
Pennsylvania (109)
Puerto Rico (1)
Rhode Island (2)
South America (40)
South Carolina (1)
Southern California (652)
Tennessee (4)
Texas (152)
United States (3202)
Utah (5)
Virginia (11)
Washington D.C. (3)
Washington State (95)
West Virginia (1)
Wisconsin (13)
40,125 Results for "imago biosciences".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Deals
Merck to Acquire Imago BioSciences, Inc.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO) today announced that the companies have entered into a definitive agreement under which Merck, through a subsidiary, will acquire Imago for $36.00 per share in cash for an approximate total equity value of $1.35 billion.
November 21, 2022
·
15 min read
Biotech Bay
Imago BioSciences to Participate in Upcoming November 2022 Investor Conferences
Imago BioSciences, Inc. announced that Hugh Young Rienhoff, Jr., M.D., Imago’s Chief Executive Officer, will participate in two upcoming investor conferences.
November 7, 2022
·
2 min read
Deals
Merck Completes Tender Offer to Acquire Imago BioSciences, Inc.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the successful completion of the cash tender offer, through a subsidiary, for all of the outstanding shares of common stock of Imago BioSciences, Inc.
January 11, 2023
·
4 min read
Deals
Merck Begins Tender Offer to Acquire Imago BioSciences, Inc.
Merck (NYSE: MRK), known as MSD outside of the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Imago BioSciences, Inc.
December 12, 2022
·
7 min read
Biotech Bay
Imago BioSciences to Participate in the 2022 Wedbush PacGrow Healthcare Conference
Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today announced that Hugh Young Rienhoff, Jr., MD, CEO of Imago BioSciences, will participate in an analyst led Fireside Chat at the 2022 Wedbush PacGrow Healthcare Conference.
August 3, 2022
·
1 min read
Biotech Bay
Imago BioSciences to Participate in Upcoming Investor Conferences - May 16, 2022
Imago BioSciences, Inc. announced that Hugh Young Rienhoff, Jr., M.D., Imago’s Chief Executive Officer, will participate in three upcoming investor conferences.
May 16, 2022
·
5 min read
Business
Imago BioSciences Reports Third Quarter 2022 Financial Results and Provides Recent Business Updates
Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today reported financial results for the third quarter ended September 30, 2022 and provided a corporate update.
November 9, 2022
·
10 min read
Drug Development
Imago BioSciences Announces First Participant Dosed in Investigator-Sponsored Phase 2 Study of Bomedemstat in Combination with Ruxolitinib in Myelofibrosis
Imago BioSciences, Inc. (“Imago” or the “Company”) (Nasdaq: IMGO) today announced that the first participant has been dosed in an investigator-sponsored Phase 2 study of bomedemstat, an investigational oral lysine-specific demethylase 1 (LSD1) inhibitor, in combination with ruxolitinib (Jakafi®) in people with myelofibrosis (MF).
December 20, 2022
·
6 min read
Biotech Bay
Imago BioSciences to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Imago BioSciences, Inc. (“Imago”) (Nasdaq: IMGO), a clinical-stage biopharmaceutical company discovering and developing new medicines for the treatment of myeloproliferative neoplasms (MPNs) and other bone marrow diseases, today announced that Hugh Young Rienhoff, Jr., MD, CEO of Imago BioSciences, will participate in the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12 - 14, 2022.
September 6, 2022
·
1 min read
Business
Imago BioSciences Reports Second Quarter 2022 Financial Results and Provides Recent Business Updates
Imago BioSciences, Inc. (“Imago” or the “Company”) (Nasdaq: IMGO), today reported financial results for the second quarter ended June 30, 2022 and provided business updates.
August 12, 2022
·
13 min read
1 of 4,013
Next